Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
1. OSTX's Phase 2b trial shows significant 12-month event-free survival rates. 2. OST-HER2 treatment achieved 33% EFS vs. 20% historical controls. 3. 1-year overall survival was 91% in OST-HER2 vs. 80% controls. 4. Company raised $6 million for clinical support and commercialization. 5. OSTX stock rose 7.96% after positive trial data announcement.